(S)-1-(4-methanesulfonamidophenoxy)-3-(3,4-dichlorophenylethylamino)-2-propanol | 457897-92-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-1-(4-methanesulfonamidophenoxy)-3-(3,4-dichlorophenylethylamino)-2-propanol
• 英文别名: N-{4-[(2S)-3-{[2-(3,4-dichlorophenyl)ethyl]amino}-2-hydroxypropoxy]phenyl}methanesulfonamide；N-[4-[(2S)-3-[2-(3,4-dichlorophenyl)ethylamino]-2-hydroxypropoxy]phenyl]methanesulfonamide
• CAS: 457897-92-6
• 化学式: C₁₈H₂₂Cl₂N₂O₄S
• 分子量: 433.356
• InChiKey: GEFDXUZHLNJUMR-HNNXBMFYSA-N

物化性质

• 沸点：
  611.8±65.0 °C(Predicted)
• 密度：
  1.392±0.06 g/cm3(Predicted)
• 溶解度：
  DMF：12.5mg/mL； DMSO：14mg/mL； DMSO:PBS (pH 7.2) (1:10)：0.1 mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  27
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  96
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (S)-1-(4-methanesulfonamidophenoxy)-3-(3,4-dichlorophenylethylamino)-2-propanol 在 盐酸 作用下， 以 乙醇 为溶剂， 生成 (S)-1-(4-methanesulfonamidophenoxy)-3-(3,4-dichlorophenylethylamino)-2-propanol hydrochloride
  参考文献：
  名称：

  Enantiomeric Propanolamines as selective N-Methyl-d-aspartate 2B Receptor Antagonists

  摘要：

  Enantiomeric propanolamines have been identified as a new class of NR2B-selective NMDA receptor antagonists. The most effective agents are biaryl structures, synthesized in six steps with overall yields ranging from 11-64%. The compounds are potent and selective inhibitors of NR2B-containing recombinant NMDA receptors with IC50 values between 30-100 nM. Potency is strongly controlled by substitution on both rings and the centrally located amine nitrogen. SAR analysis suggests that well-balanced polarity and chain-length factors provide the greatest inhibitory potency. Structural comparisons based on 3D shape analysis and electrostatic complementarity support this conclusion. The antagonists are neuroprotective in both in vitro and in vivo models of ischemic cell death. In addition, some compounds exhibit anticonvulsant properties. Unlike earlier generation NMDA receptor antagonists and some NR2B-selective antagonists, the present series of propanolamines does not cause increased locomotion in rodents. Thus, the NR2B-selective antagonists exhibit a range of therapeutically interesting properties.

  DOI：

  10.1021/jm8002153
• 作为产物：
  描述：

  4-(2-环氧乙烷基甲氧基)苯胺 在 N,N-二异丙基乙胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 生成 (S)-1-(4-methanesulfonamidophenoxy)-3-(3,4-dichlorophenylethylamino)-2-propanol
  参考文献：
  名称：

  Novel GluN2B-Selective NMDA Receptor Negative Allosteric Modulator Possesses Intrinsic Analgesic Properties and Enhances Analgesia of Morphine in a Rodent Tail Flick Pain Model

  摘要：

  DOI：

  10.1021/acschemneuro.2c00779

文献信息

• Ph-dependent nmda receptor antagonists
  申请人：——

  公开号：US20040138502A1

  公开（公告）日：2004-07-15

  NMDA receptor blockers, including pH-sensitive NMDA receptor blockers, are provided as neuroprotective drugs that are useful in stroke, traumatic brain injury, epilepsy, and other neurologic events that involve acidification of brain or spinal cord tissue. Compositions and methods of this invention are used for treating neurodegeneration resulting from NMDA receptor activation. The compounds described herein have enhanced activity in brain tissue having lower-than normal pH due to pathological conditions such as hypoxia resulting from stroke, traumatic brain injury, global ischemia tat may occur during cardiac surgery, hypoxia tat may occur following cessation of breathing, pre-eclampsia, spinal cord trauma, epilepsy, chronic pain, vascular dementia and glioma tumors. Compounds described herein are also useful in preventing neurodegeneration in patients with Parkinson's Alzheimer's, Huntington's chorea, ALS, and other neurodegenerative conditions known to the art to be responsive to treatment using NMDA receptor blockers. Preferably the compounds provided herein are allosteric NMDA inhibitors.

  NMDA受体阻滞剂，包括pH敏感的NMDA受体阻滞剂，被提供作为神经保护药物，可用于中风、创伤性脑损伤、癫痫和其他涉及大脑或脊髓组织酸化的神经事件。本发明的组合物和方法用于治疗由NMDA受体激活引起的神经退行性疾病。所述化合物在具有低于正常pH的脑组织中具有增强的活性，这是由于病理条件（如中风引起的低氧血症、创伤性脑损伤、在心脏手术期间可能发生的全局缺血、呼吸停止后可能发生的低氧血症、妊娠期高血压综合症、脊髓损伤、癫痫、慢性疼痛、血管性痴呆和胶质瘤等）。所述化合物也可用于预防帕金森病、阿尔茨海默病、亨廷顿舞蹈症、肌萎缩侧索硬化症和其他已知对使用NMDA受体阻滞剂治疗有反应的神经退行性疾病患者的神经退行性。优选地，本文提供的化合物是变构NMDA抑制剂。
• PH-dependent NMDA receptor antagonists
  申请人：Traynelis Stephen F.

  公开号：US20090023791A1

  公开（公告）日：2009-01-22

  NMDA receptor blockers, including pH-sensitive NMDA receptor blockers, are provided as neurprotective drugs that are useful in stroke, traumatic brain injury, epilepsy, and other neurologic events that involve acidification of brain or spinal cord tissue. Compositions and methods of this invention are used for treating neurodegeneration resulting from NMDA receptor activation. The compounds described herein have enhanced activity in brain tissue having lower than normal pH due to pathological conditions such as hypoxia resulting from stroke, traumatic brain injury, global ischemia that may occur during cardiac surgery, hypoxia that may occur following cessation of breathing, pre-eclampsia, spinal cord trauma, epilepsy, chrounic pain, vascular dementia and glioma rumors. Compounds described herein are also useful in preventing neurodegeneration in patients with Parkinson's Alzheimer's, Huntington's chorea, ALS, and other neurodegenerative conditions known to the art to be responsive to treatment using NMDA receptor blockers. Prefebably the compounds provided herein are allosteric NMDA inhibitors.

  NMDA受体阻滞剂，包括pH敏感的NMDA受体阻滞剂，作为神经保护药物提供，可用于中风、创伤性脑损伤、癫痫和其他涉及脑或脊髓组织酸化的神经事件。本发明的组合物和方法用于治疗由NMDA受体激活引起的神经退行性疾病。所述化合物在具有低于正常pH的脑组织中具有增强的活性，这是由于病理情况（如中风、创伤性脑损伤、可能发生于心脏手术期间的全球性缺血、呼吸停止后可能发生的低氧、先兆子痫、脊髓损伤、癫痫、慢性疼痛、血管性痴呆和胶质瘤）所致。所述化合物还可用于预防帕金森病、阿尔茨海默病、亨廷顿舞蹈症、肌萎缩侧索硬化症和其他已知对使用NMDA受体阻滞剂治疗有响应的神经退行性疾病患者的神经退行性。最好所提供的化合物是变构的NMDA抑制剂。
• US7375136B2
  申请人：——

  公开号：US7375136B2

  公开（公告）日：2008-05-20
• Enantiomeric Propanolamines as selective <i>N</i>-Methyl-<scp>d</scp>-aspartate 2B Receptor Antagonists
  作者：Yesim A. Tahirovic、Matthew Geballe、Ewa Gruszecka-Kowalik、Scott J. Myers、Polina Lyuboslavsky、Phuong Le、Adam French、Hasan Irier、Woo-baeg Choi、Keith Easterling、Hongjie Yuan、Lawrence J. Wilson、Robert Kotloski、James O. McNamara、Raymond Dingledine、Dennis C. Liotta、Stephen F. Traynelis、James P. Snyder

  DOI：10.1021/jm8002153

  日期：2008.9.25

  Enantiomeric propanolamines have been identified as a new class of NR2B-selective NMDA receptor antagonists. The most effective agents are biaryl structures, synthesized in six steps with overall yields ranging from 11-64%. The compounds are potent and selective inhibitors of NR2B-containing recombinant NMDA receptors with IC50 values between 30-100 nM. Potency is strongly controlled by substitution on both rings and the centrally located amine nitrogen. SAR analysis suggests that well-balanced polarity and chain-length factors provide the greatest inhibitory potency. Structural comparisons based on 3D shape analysis and electrostatic complementarity support this conclusion. The antagonists are neuroprotective in both in vitro and in vivo models of ischemic cell death. In addition, some compounds exhibit anticonvulsant properties. Unlike earlier generation NMDA receptor antagonists and some NR2B-selective antagonists, the present series of propanolamines does not cause increased locomotion in rodents. Thus, the NR2B-selective antagonists exhibit a range of therapeutically interesting properties.
• Novel GluN2B-Selective NMDA Receptor Negative Allosteric Modulator Possesses Intrinsic Analgesic Properties and Enhances Analgesia of Morphine in a Rodent Tail Flick Pain Model
  作者：Lynnea D. Harris、Michael C. Regan、Scott J. Myers、Kelsey A. Nocilla、Nicholas S. Akins、Yesim A. Tahirovic、Lawrence J. Wilson、Ray Dingledine、Hiro Furukawa、Stephen F. Traynelis、Dennis C. Liotta

  DOI：10.1021/acschemneuro.2c00779

  日期：2023.3.1